

**2ND INTERNATIONAL RESEARCH MEETING**  
**3<sup>D</sup> JUNE 2010- HÔTEL DE MARIGNY PARIS**

**2009 CNS MEETING FOLLOW-UP: WHAT HAS CHANGED ?**

**FINAL PROGRAM**

- 16H00 PM: Official opening by the Minister Madame Roselyne Bachelot**
- 16H30 PM: Introduction by Pharmaceutical Industry representatives:** Dominique Amory and Christian Lajoux
- 16H45 PM: The key success factors for a successful public private partnership in life sciences:**  
Video of Elias Zerhouni
- 16H50 PM: ROUNDTABLE DISCUSSION: WHAT HAS CHANGED SINCE LAST YEAR?**
- Key data and information : Pr Alexis Brice
  - Selected Public-private partnerships Case studies:
    - **Eli Lilly & MIRCEN**
      - **Eli Lilly : Michael Hutton** Chief Scientific Officer  
Neurodegenerative Platform
      - **Mircen (Molecular Imaging Research Center - site du CEA):**
        - **Dr Philippe Hantraye**
        - Dr Nicole Déglon
    - **AstraZeneca & NEUROSPIN**
      - **AstraZeneca (R&D Global Neuroscience):**
        - **Mattias Lindberg**, Senior Responsible Scientist,
        - **Patrick Raboisson**, Director, Analgesia Disease.
      - **Neurospin :**
        - **Dr Jean-René Deverre**, Neurospin platform director,
        - **Dr Denis LeBihan**, General Director

- **Roche & ICM & CLINATEC**
  - **General Introduction : Sophie Kornowski-Bonnet**, General Manager Roche France : **Roche involvement and participation in CNS**
  - **Roche - Clinec**
    - **Roche Jean-Luc Moreau**, Scientific Expert - Extramural Neuroscience & Operations Manager
    - **Clinec : Pr François Berger**, Directeur de recherche Inserm, Nanomédecine et cerveau, University of Grenoble
  - **Roche – ICM/ IM2A**
    - **Thomas Blaettler**, Clinical Science Leader Neuroscience
    - **Pr Bruno Dubois**, CHU Pitié Salpêtrière, IM2A (Institut de la mémoire et de la maladie d’Alzheimer)
- P. Amouyel - Public-private partnerships in the context of the foundation for scientific cooperation “Alzheimer’s disease and related diseases”
- Quelques exemples et commentaires complémentaires de la part d’autres industriels
  - **Sanofi aventis : Marc Cluzel Executive VP Head of R&D “Partenariat entre Sanofi Aventis et l’Alliance Aviesan”**
  - **Ipsen : Dr. Claude Bertrand Executive Vice-President, Chief Scientific Officer**
  - **Janssen : Dr. Luc Van Hijfte, Sr Director, Head Medicinal Chemistry European Discovery Capabilities A division of Janssen-Pharmaceuticals**
  - **Pfizer : Olivier Drap, Associate Director, R&D Business Development à Sandwich (UK)**  
« Place of France in Public-private partnerships” at the European level »
- Importance of education and training for efficient and productive PPP
- **Prof Jean-Marie Goehrs**

**18H15 PM: Conclusion by Arnold Munich and André Syrota (Chairman of Aviesan)**